Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate visual improvement in patients treated with Immune Globulin
Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) or placebo who have
Age-Related Macular Degeneration (AMD) with occult Choroidal Neovascularization (CNV).
Phase:
Phase 2
Details
Lead Sponsor:
Grifols Therapeutics Inc. Grifols Therapeutics LLC
Treatments:
Antibodies gamma-Globulins Immunoglobulin G Immunoglobulins Immunoglobulins, Intravenous Rho(D) Immune Globulin